Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (108)

Latest Posts

About This Stock More About This Stock
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Article By: Benzinga
Thursday, May 27, 2021 9:00 AM EDT
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021.
In this article: SNY, GSK
Read
70 Firms Going Ex-Dividend Next Week, Including Walmart, BP And Pfizer
Article By: Timothy J. McIntosh
Saturday, May 1, 2021 8:28 PM EDT
There are several well known large cap stocks going ex-dividend next week. Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
In this article: AEP, BP, IBM, PFE, SNY, WFC, WMT, INTC, O
Read
E Daily Stock Analysis: Sanofi (SNY)
Article By: Fredrik Arnold
Wednesday, April 28, 2021 5:58 AM EDT
Sanofi's price per share closed at $51.50 yesterday. One year ago its price was $49.87.
In this article: SNY
Read
E Daily Stock Analysis: Sanofi
Article By: Fredrik Arnold
Sunday, April 4, 2021 7:55 PM EDT
Should Sanofi's stock trade in the range of $40 to $65 this year, its recent $49.67 price might rise by $10.64 to reach $60.00 by April 5, 2022.
In this article: SNY
Read
Sanofi, GSK Delay COVID Vaccine On Low Response In Older Adults
Article By: The Fly
Friday, December 11, 2020 8:25 AM EDT
Sanofi and GlaxoSmithKline announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults.
In this article: GSK, SNY
Read

Latest Tweets for $SNY

No tweets yet!

$SNY

There Is Beta In Protalix Stock Due To PRX-102
Paul McGee 8/28/2020 2:44:13 AM

Isn't that made by Sanofi $SNY?

Protalix BioTherapeutics Pipeline Progress
Harry Goldstein 8/10/2020 6:01:37 AM

#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY

Protalix BioTherapeutics Pipeline Progress
Old Time Investor 8/3/2020 2:23:12 PM

My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.

1 to 3 of 3 comments